Burlingame, CA – According to filings with the U.S. Securities and Exchange Commission, Genesis Therapeutics is raising $49,517,631.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Evan Feinberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Genesis Therapeutics

We’re a mission-driven group of deep learning researchers, software engineers, and proven drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies. Through internal programs and selective partnerships with top pharmaceutical companies, we’re improving every stage of drug development, and ultimately transforming the lives of patients suffering from severe disorders.

To learn more about Genesis Therapeutics, visit http://www.genesistherapeutics.ai/

Contact:
Evan Feinberg, President and Chief Executive Officer
203-615-4567
evan@genesistherapeutics.ai
https://www.linkedin.com/in/evanfeinberg/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved